Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grand Pharmaceutical Group (FRA:MX6A) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Grand Pharmaceutical Group Forward PE Ratio Related Terms
Grand Pharmaceutical Group Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group Forward PE Ratio Chart
Grand Pharmaceutical Group Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
7.47
11.37
Grand Pharmaceutical Group Semi-Annual Data
2024-12
2025-06
2025-12
Forward PE Ratio
7.47
13.38
11.37
FRA:MX6A vs ZTS: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Pharmaceutical Group Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Grand Pharmaceutical Group's Forward PE Ratio falls into.
Grand Pharmaceutical Group Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Grand Pharmaceutical Group (FRA:MX6A) has a Forward PE Ratio of 11.12 as of Aug. 23, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Grand Pharmaceutical Group and its competitors. According to the industry distribution chart, Grand Pharmaceutical Group ranks #116 out of 409 companies in the Drug Manufacturers industry, placing it in the top 28.4%.
Is Grand Pharmaceutical Group's Forward PE Ratio too high?
Grand Pharmaceutical Group's current Forward PE Ratio is 11.12. The Drug Manufacturers industry median Forward PE Ratio is 17.51. Grand Pharmaceutical Group's value of 11.12 is 36.5% below this industry median. Based on the distribution chart, Grand Pharmaceutical Group ranks #116 out of 409 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grand Pharmaceutical Group has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's Forward PE Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #116 out of 409 companies for Forward PE Ratio. This puts Grand Pharmaceutical Group in the upper half of its industry. The industry median Forward PE Ratio is 17.51. Grand Pharmaceutical Group's value of 11.12 is 36.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.51, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Pharmaceutical Group's current Forward PE Ratio of 11.12 is 36.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Grand Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current Forward PE Ratio is 11.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Grand Pharmaceutical Group (FRA:MX6A) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.62, compared to a current price of €0.55 — trading 12.1% below its estimated fair value. The current Forward PE Ratio is 11.12 and 36.5% below the Drug Manufacturers industry median of 17.51. Grand Pharmaceutical Group's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Grand Pharmaceutical Group (FRA:MX6A), the current Forward PE Ratio is 11.12 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grand Pharmaceutical Group (FRA:MX6A) Overvalued in 2026?
Based on GuruFocus' analysis, Grand Pharmaceutical Group stock appears to be undervalued.
The current stock price of €0.55 is trading 12.1% below its estimated GF Value™ of €0.62.
GuruFocus considers Grand Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for FRA:MX6A:
Forward PE Ratio: 11.12
GF Value™: €0.62 vs. price of €0.55 (12.1% below fair value)
Industry Position: 36.5% below the Drug Manufacturers median (#116 of 409)
No single metric tells the full story. See the FRA:MX6A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
87GF Score
Get the complete analysis for FRA:MX6A
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MX6A has been successfully added to your 
